Breakthrough COVID-19 in Vaccinated Patients with Haematologic Malignancies—The First Single-Centre Experience from the Czech Republic
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00098892%3A_____%2F22%3A10157304" target="_blank" >RIV/00098892:_____/22:10157304 - isvavai.cz</a>
Alternative codes found
RIV/61989592:15110/22:73614559
Result on the web
<a href="https://www.mdpi.com/2075-1729/12/8/1184" target="_blank" >https://www.mdpi.com/2075-1729/12/8/1184</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3390/life12081184" target="_blank" >10.3390/life12081184</a>
Alternative languages
Result language
angličtina
Original language name
Breakthrough COVID-19 in Vaccinated Patients with Haematologic Malignancies—The First Single-Centre Experience from the Czech Republic
Original language description
Vaccination is an important tool in the fight against the COVID-19 pandemic in patients with haematologic malignancies. The paper provides an analysis of the course of breakthrough SARS-CoV-2 infection in a group of vaccinated patients with haematological malignancy and a comparison with a historical cohort of 96 non-vaccinated patients with haematologic malignancies and bone marrow failure syndromes (two patients) in the treatment of COVID-19. A severe or critical course of COVID-19 was significantly less frequent in the group of vaccinated patients (10.2% vs. 31.4%, p = 0.003). The need for hospitalisation due to COVID-19 was significantly lower in vaccinated patients (27.1% vs. 72.6%, p < 0.0001) and the duration of hospitalisation was significantly shorter (10 vs. 14 days, p = 0.045). Vaccinated patients were insignificantly less likely to require oxygen therapy during infection. COVID-19 mortality was significantly higher in non-vaccinated patients (15.6% vs. 5.1%, p = 0.047). The paper demonstrated a significant positive effect of vaccination against COVID-19 on a less severe clinical course of infection, lower need for hospitalisation and mortality. However, the results need to be evaluated even in the context of new antivirals and monoclonal antibodies against SARS-CoV-2 or virus mutations with different biological behaviour.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Life
ISSN
2075-1729
e-ISSN
2075-1729
Volume of the periodical
12
Issue of the periodical within the volume
8
Country of publishing house
CH - SWITZERLAND
Number of pages
10
Pages from-to
1184
UT code for WoS article
000845409800001
EID of the result in the Scopus database
2-s2.0-85137347368